Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study
NCT ID: NCT04926233
Last Updated: 2021-11-15
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1371146 participants
OBSERVATIONAL
2019-11-15
2020-04-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COPD patients from US IBM Marketscan database
Tiotropium bromide + Olodaterol
Tiotropium bromide + Olodaterol
Sp(t)iolto® Respimat®
Sp(t)iolto® Respimat®
COPD patients from UK CPRD GOLD database
Tiotropium bromide + Olodaterol
Tiotropium bromide + Olodaterol
Sp(t)iolto® Respimat®
Sp(t)iolto® Respimat®
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tiotropium bromide + Olodaterol
Tiotropium bromide + Olodaterol
Sp(t)iolto® Respimat®
Sp(t)iolto® Respimat®
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
\-- COPD diagnosis
* child cohort
\-- any initiation of first maintenance therapy after July 1, 2015
* grandchild cohort -- any initiation of second maintenance therapy after August 2, 2015
Exclusion Criteria
* age \<40 on index date
* any COPD diagnosis in baseline
* any use of long-acting muscarinic antagonists (LAMA), long-acting beta-agonists (LABA), or inhaled corticosteroid (ICS) in baseline
* \<365 days of continuous medical and pharmacy coverage
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AETION inc
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1237-0091
Identifier Type: -
Identifier Source: org_study_id